Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in gynecologic cancers. The first approval is for Keytruda ...

Merck Research Laboratories. "These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab ... who have not received prior definitive therapy. The EC approvals are based on results from two late-stage trials ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, has received approval from the European Commission (EC) for two new indications of its anti-PD-1 therapy, KEYTRUDA ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, has received approval from the European Commission (EC) for two new indications of its anti-PD-1 therapy, KEYTRUDA® ...

a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti ...

ByInvesting.com • Sep 22, 2023 Merck Granted FDA Priority Review for KEYTRUDA Plus Concurrent Chemoradiotherapy ... announced today that the European Commission (EC) has approved an expanded ...